The Effect of Zinc on Hemoglobin in Hemodialysis Patients

Phase 3

Recruiting

Conditions: Condition 1: End stage renal disease on hemodialysis. Condition 2: Anemia.
Dependence on renal dialysis
End stage renal disease
Z99.2
N18.6

Registration Number: IRCT20200827048539N1

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

Patients who have been on hemodialysis for at least 3 months
More than 18 years of age
Consensus on participation in the study
Hemoglobin level less than 12 g/dl
Patients who are under ongoing therapy with injected erythropoetin
Not taking cholrthalidone, tetracycline and penicillin
Non pregnant and breastfeeding
On hemodialysis for at least twice a week
Not having cancer, acute inflammatory disease and severe hepatic failure

Exclusion Criteria

Patients wanting to discontinue the cooperation for any reason
Discontinuing hemodialysis therapy
Surgical operation during the study
Blood transfusion during the study
Hemorrhage during the study
Development of malignant tumors during the study
Pregnancy during the study
Intolerance of drug
Non-compliance with the intervention (less than 70%)

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood hemoglobin level. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: Hemoglobin measurement by automated hematology analyzer, sysmex-21N, Japan.

Secondary Outcome Measures

Name	Time	Method
The amount of prescribed erythropoetin. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: By observation and questionnaire.;Serum zinc level. Timepoint: Before, 3 and 6 months after the intervention. Method of measurement: Laboratory AUDIT kit (Delta Darman Part, Tehran, Iran), measured by OLYMPUS 2700 autoanalyzer, Japan.